DESOXYN Drug Patent Profile

Which patents cover Desoxyn, and what generic alternatives are available?

Desoxyn is a drug marketed by Ajenat Pharms and is included in one NDA.

The generic ingredient in DESOXYN is methamphetamine hydrochloride. There is one drug master file entry for this compound. Three suppliers are listed for this compound. Additional details are available on the methamphetamine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Desoxyn

A generic version of DESOXYN was approved as methamphetamine hydrochloride by DR REDDYS LABS SA on April 21^st, 2010.

Summary for DESOXYN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	33
Clinical Trials:	5
Patent Applications:	3,939
Drug Prices:	Drug price information for DESOXYN
What excipients (inactive ingredients) are in DESOXYN?	DESOXYN excipients list
DailyMed Link:	DESOXYN at DailyMed

See drug prices for DESOXYN

Recent Clinical Trials for DESOXYN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of California, San Francisco	Phase 4
National Institute on Drug Abuse (NIDA)	Phase 4
Portland VA Medical Center	Phase 4

See all DESOXYN clinical trials

US Patents and Regulatory Information for DESOXYN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Ajenat Pharms	DESOXYN	methamphetamine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	005378-004	Approved Prior to Jan 1, 1982		DISCN	No	No
Ajenat Pharms	DESOXYN	methamphetamine hydrochloride	TABLET;ORAL	005378-002	Approved Prior to Jan 1, 1982	AA	RX	Yes	Yes
Ajenat Pharms	DESOXYN	methamphetamine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	005378-003	Approved Prior to Jan 1, 1982		DISCN	No	No

Desoxyn Market Dynamics, Patent Status, FDA Exclusivity, and Financial Trajectory

Last updated: September 15, 2026

Desoxyn is an FDA-approved methamphetamine hydrochloride tablet marketed for limited use in attention-deficit/hyperactivity disorder and short-term adjunctive treatment of exogenous obesity. Its commercial market is small, highly controlled, and structurally exposed to generic substitution. The product has no meaningful remaining new-drug exclusivity, no biosimilar exposure, and limited publicly reported financial visibility. Its value depends more on reliable controlled-substance supply and prescriber willingness than on patent protection.

What is Desoxyn and what is its FDA regulatory status?

Desoxyn contains methamphetamine hydrochloride, a central nervous system stimulant classified by the Drug Enforcement Administration as a Schedule II controlled substance. The product is supplied as 5 mg tablets under FDA NDA 005378. Its approved indications are narrow compared with the broader stimulant market. [1]

Attribute	Desoxyn
Active ingredient	Methamphetamine hydrochloride
Dosage form	Immediate-release oral tablet
Strength	5 mg
FDA application	NDA 005378
Controlled-substance schedule	Schedule II
Primary approved indication	ADHD
Secondary approved indication	Short-term adjunct for exogenous obesity
FDA pathway	Original new drug application
Biosimilar relevance	None
Current commercial model	Specialty, low-volume prescription product

The FDA labeling positions Desoxyn as a treatment option after other recommended medications have proved inadequate or produced unacceptable adverse effects. The label also contains substantial warnings involving abuse, misuse, addiction, cardiovascular effects, psychiatric symptoms, growth suppression, and overdose risk. [1]

The obesity indication is commercially less important than the ADHD indication. Current obesity treatment has shifted toward GLP-1 receptor agonists, dual incretin therapies, and other branded therapies with stronger clinical and commercial support. Methamphetamine’s abuse liability and narrow label reduce its relevance in modern obesity prescribing.

When does Desoxyn lose exclusivity?

Desoxyn’s original regulatory exclusivity expired decades ago. The product was approved under an old NDA, and any original active-ingredient, regulatory, or market exclusivity period is no longer commercially relevant.

The principal market-access barriers are now:

• Controlled-substance manufacturing quotas.
• DEA registration and compliance requirements.
• FDA approval of an ANDA or other lawful abbreviated pathway.
• Commercial willingness to manufacture and distribute a low-volume Schedule II product.
• Pharmacy and wholesaler willingness to maintain inventory.
• Prescriber reluctance caused by abuse and diversion concerns.

Desoxyn is therefore a post-exclusivity product whose competitive position is determined by supply economics rather than by statutory exclusivity.

What patents protect Desoxyn?

Desoxyn’s core active ingredient and basic immediate-release tablet technology are old. No commercially meaningful patent moat remains around methamphetamine hydrochloride as an active pharmaceutical ingredient.

The FDA Orange Book is the relevant source for determining whether patents are listed against NDA 005378. An old product may have no currently relevant listed patents even if historical patents once covered manufacturing, formulation, or use. Orange Book patent listings also do not capture every possible patent theory that a litigant could assert. [2]

Protection category	Desoxyn position
New chemical entity exclusivity	Expired
Pediatric exclusivity	No current commercial relevance identified
Core compound patent	Expired
Immediate-release tablet patent	No meaningful remaining protection expected
Formulation patent	No publicly established commercial moat
Method-of-use patent	No dominant current patent barrier identified
Orphan-drug exclusivity	Not applicable
Biosimilar exclusivity	Not applicable

What formulations are protected by Desoxyn patents?

Desoxyn is an immediate-release tablet rather than a long-acting delivery system. Publicly available FDA materials do not establish a current, commercially important patent estate covering an extended-release, abuse-deterrent, transdermal, injectable, or other differentiated Desoxyn formulation. [1]

A company could theoretically pursue a new formulation under a separate FDA application. Such a product would need to establish clinical, pharmacokinetic, or safety differentiation and would compete against established stimulant delivery systems, including extended-release amphetamine and methylphenidate products.

Is Desoxyn listed in the Orange Book?

Desoxyn is associated with FDA NDA 005378. The Orange Book is the controlling source for current patent and exclusivity listings. Products with an old NDA and no active listed patent generally face a direct generic pathway, subject to FDA approval and controlled-substance manufacturing capacity. [2]

The commercial implication is important: an absence of listed patents removes a major litigation obstacle, but it does not guarantee immediate generic entry. A potential applicant still must demonstrate pharmaceutical equivalence and bioequivalence, satisfy FDA manufacturing requirements, secure DEA authorization, and establish a viable supply chain.

Are there Paragraph IV challenges to Desoxyn?

Publicly available FDA and litigation records do not indicate a major, commercially consequential Paragraph IV campaign directed at Desoxyn. That outcome is consistent with the product’s small market and weak patent economics.

Paragraph IV litigation is generally attractive when:

1. The branded product has substantial annual sales.
2. The patent estate has meaningful remaining life.
3. Several generic applicants can compete for first-filer economics.
4. The market can support multiple manufacturers after launch.

Desoxyn does not strongly satisfy those conditions. If no relevant Orange Book patents are listed, a Paragraph IV certification would not be the central entry mechanism. A generic applicant could instead pursue an ordinary ANDA pathway against the reference listed drug, subject to the statutory and regulatory requirements applicable to the application.

How strong is the Desoxyn patent estate?

The Desoxyn patent estate is weak from a lifecycle-management perspective.

Patent-strength factor	Assessment
Remaining patent life	Minimal or none at the product level
Patent density	Low
Formulation differentiation	Limited
Method-of-use protection	Limited
Litigation leverage	Low
Generic deterrence	Primarily operational, not legal
Ability to extend exclusivity	Low without a new formulation or indication

The more durable barriers are operational. Methamphetamine is a controlled substance, and manufacturers must comply with DEA production quotas, security requirements, recordkeeping, distribution controls, and diversion-prevention obligations. The Controlled Substances Act also limits manufacturing flexibility compared with ordinary generic tablets. [3]

These controls can reduce the number of willing suppliers even when patent protection is absent. They can also increase the impact of a manufacturing interruption because a replacement supplier cannot necessarily scale production quickly.

What generic entry risks exist for Desoxyn?

The generic-entry risk is structurally high but commercially uncertain.

A generic methamphetamine hydrochloride tablet could erode the branded product if an applicant obtains FDA approval and secures sufficient DEA quota. The likely commercial effect would depend on the number of entrants, reimbursement terms, wholesaler distribution, pharmacy substitution, and whether the brand retains a supply or prescriber advantage.

Generic-entry scenario	Likely effect on Desoxyn
No approved generic	Brand retains a niche monopoly, subject to supply risk
One approved generic	Moderate price pressure and payer substitution
Multiple approved generics	Significant price erosion and possible brand displacement
Generic approval without reliable supply	Limited immediate impact
New branded formulation	Could shift demand away from immediate-release tablets

The small market creates a paradox. Low sales reduce the incentive for generic entry, but low volume can also make a single generic manufacturer economically viable if manufacturing costs are controlled and competition remains limited.

Which companies are challenging Desoxyn?

No major publicly documented litigation campaign or named generic challenger has become a defining feature of the Desoxyn market. The competitive threat is better characterized as latent ANDA risk than as active patent litigation.

Potential competitors include generic manufacturers with Schedule II capabilities and companies already producing controlled-release stimulant products. However, manufacturing a different stimulant, such as mixed amphetamine salts or methylphenidate, does not create automatic substitutability. A generic methamphetamine hydrochloride product would need to meet the FDA’s equivalence requirements for the Desoxyn reference product.

How does Desoxyn compare with competing ADHD drugs?

Desoxyn competes in the ADHD market against amphetamine and methylphenidate products, including Adderall, Vyvanse, Concerta, Ritalin, and their generic equivalents. It also competes indirectly with nonstimulants such as atomoxetine, guanfacine extended-release, and clonidine extended-release.

Product class	Examples	Commercial position versus Desoxyn
Methamphetamine	Desoxyn	Very narrow use; high stigma and control burden
Mixed amphetamine salts	Adderall and generics	Much broader prescribing and generic availability
Lisdexamfetamine	Vyvanse and generics	Long-acting profile and large historical market
Methylphenidate	Concerta, Ritalin, and generics	Broad pediatric and adult use
Nonstimulants	Atomoxetine, guanfacine	Lower abuse potential; different efficacy and tolerability profile
Digital and behavioral interventions	Various	Adjunctive or alternative role, not direct substitutes

The main disadvantages are methamphetamine’s abuse potential, limited physician familiarity, constrained distribution, and narrow positioning in treatment guidelines. The main commercial advantage is that it remains an FDA-approved option for selected patients who do not respond adequately to other stimulants.

What is the financial trajectory of Desoxyn?

Recordati’s public reporting does not generally provide a separately reported Desoxyn revenue line. The product’s revenue contribution therefore cannot be isolated reliably from public company filings. [4]

The financial trajectory is best described as a low-growth, low-visibility niche product with limited upside and meaningful downside from generic entry or supply interruption.

Revenue drivers

Desoxyn revenue is influenced by:

• Prescription volume in treatment-resistant ADHD.
• Continued availability through pharmacies and wholesalers.
• The absence of a reliable generic competitor.
• Reimbursement for a high-control, low-volume product.
• Prescriber willingness to use methamphetamine after other stimulants fail.
• The size of the adult ADHD treatment population.

Revenue pressures

The product faces:

• Substitution by generic amphetamine and methylphenidate.
• Increasing use of long-acting stimulant formulations.
• Expansion of nonstimulant ADHD treatments.
• Abuse, diversion, and regulatory scrutiny.
• Potential generic entry.
• Limited ability to raise volume through new indications.
• Lack of a visible patent-based price shield.

Financial scenario analysis

Scenario	Market outcome	Financial impact
Base case	Continued niche use with no major generic expansion	Stable but low revenue
Generic-entry case	One or more approved generics gain payer preference	Sharp price and share erosion
Supply-constrained case	Manufacturing or quota disruption	Temporary revenue loss and patient switching
Reformulation case	New delivery system gains FDA approval	Possible premium segment, but high development risk
Regulatory-pressure case	More restrictive stimulant controls	Lower prescribing and distribution

The most likely long-term profile is a small specialty product whose value is tied to reliable supply and limited competition rather than to high growth. No public evidence supports treating Desoxyn as a major revenue driver for its commercial owner.

What licensing deals affect Desoxyn?

No major recent licensing transaction has publicly established a new growth platform around Desoxyn. The product’s commercial history has involved ownership and distribution arrangements, but public disclosures do not identify a major deal that materially changes its patent life, FDA exclusivity, or market size.

Any licensing valuation would likely focus on:

• Historical prescription volume.
• Net price and payer mix.
• Supply continuity.
• DEA quota access.
• Generic competition.
• Product-liability exposure.
• The cost of maintaining controlled-substance compliance.

The absence of separately disclosed revenue makes external valuation difficult. A buyer would need to assess product-level prescriptions and net sales through diligence rather than relying on public annual reports.

What patent litigation affects Desoxyn?

No major active patent litigation appears to define the current Desoxyn market. This separates Desoxyn from newer branded drugs whose launch timing depends on patent settlements, Paragraph IV rulings, or entry licenses.

Litigation risk is more likely to involve:

• Product liability.
• Controlled-substance distribution.
• False claims or promotional conduct.
• Supply and contract disputes.
• Manufacturing compliance.

Those risks can affect cost and reputation but do not provide the type of market exclusivity associated with an unexpired formulation or use patent.

What generic launch scenarios should investors monitor?

The most important indicators are regulatory and operational:

1. A new ANDA listing for methamphetamine hydrochloride tablets.
2. FDA approval of a therapeutically equivalent product.
3. DEA quota allocations for an applicant.
4. Wholesaler and pharmacy distribution announcements.
5. Changes in Orange Book patent listings.
6. Medicaid and commercial payer substitution policies.
7. Changes in Desoxyn supply status or product labeling.
8. Any new branded formulation or abuse-deterrent development.

A first generic launch could have a disproportionate impact because the brand has limited patent leverage and a narrow prescriber base. The magnitude would still depend on whether the generic manufacturer can maintain uninterrupted Schedule II supply.

Key Takeaways

• Desoxyn is a 5 mg immediate-release methamphetamine hydrochloride tablet approved for ADHD and short-term adjunctive obesity treatment.
• Its original FDA exclusivity expired long ago.
• The product has little or no commercially meaningful remaining patent protection.
• No major Paragraph IV litigation or biosimilar risk defines the market.
• Generic entry is legally feasible but operationally constrained by DEA controls and low market volume.
• Desoxyn competes against much larger stimulant and nonstimulant ADHD categories.
• Public filings do not separately disclose Desoxyn revenue, preventing a reliable product-level sales estimate.
• The financial profile is a low-volume niche franchise with stable demand but limited growth potential.
• Supply continuity, DEA quota access, and generic competition are more important than patent life.
• A new formulation would be the clearest route to meaningful commercial expansion, but it would require substantial clinical, regulatory, and market-development investment.

FAQs About Desoxyn Market Exclusivity and Commercial Risk

Does Desoxyn have orphan-drug exclusivity?

No. Desoxyn is not an orphan drug, and orphan-drug exclusivity does not protect its current ADHD or obesity indications.

Can a generic manufacturer launch methamphetamine hydrochloride tablets?

Yes, subject to FDA approval, bioequivalence, manufacturing compliance, DEA registration, and adequate controlled-substance quota. The absence of a strong patent barrier supports the possibility of generic entry.

Is Desoxyn more exposed to supply risk than ordinary ADHD drugs?

Yes. Methamphetamine is a Schedule II substance, so production, distribution, inventory, and quota requirements are more restrictive than for ordinary noncontrolled medicines.

Does Desoxyn compete directly with Vyvanse?

It competes in the same broad ADHD treatment market but is not a direct formulation substitute. Vyvanse is a long-acting lisdexamfetamine product, while Desoxyn is an immediate-release methamphetamine tablet with a narrower label and greater abuse-related concern.

Could a new Desoxyn formulation restore exclusivity?

A new formulation could receive separate patent and regulatory protection if it met applicable FDA requirements. That would create a new product opportunity rather than extend the original Desoxyn exclusivity period.

References

1. U.S. Food and Drug Administration. (2023). Desoxyn (methamphetamine hydrochloride) tablets, prescribing information. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Drug Enforcement Administration. (2024). Controlled substances resources and regulations. U.S. Department of Justice.

4. Recordati S.p.A. (2023). Annual report 2023. Milan, Italy: Recordati S.p.A.